3 out of 4 (75%) patients experienced tumor shrinkage at 2 months 1 out of 4 (25%) patients experienced tumor control at 2 months 1 out of 4 patients remain on IMX-110 + tislelizumab therapy as of ...
Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results